Congress Materials

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Silverberg J, Thyssen J, Lazariciu I, Valdez H, Myers D, Guler E, Chovatiya R September 10, 2022 EADV 2022 Atopic Dermatitis

Abrocitinib Improves Itch and Quality of Life in Patients With Itch-Dominant Atopic Dermatitis

View Presentation
Poster
Thyssen J, Bewley A, Ständer S, Castro C, Misery L, Kim B, Biswas P, Chan G, Myers D, Watkins M, Alderfer J, Guler E, Silverberg J September 10, 2022 EADV 2022 Atopic Dermatitis

Abrocitinib Improves Skin Pain and Quality of Life Outcomes in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

View Presentation
Oral Presentation
Guttman-Yassky E, Weidinger S, Bissonette R, Armstrong A, Seneschal J, Eyerich K, Estrada Y, Pavel A, Xu D, Chen A, Tatulych S, Guler E, Chan G, Page K, Kerkmann U, Valdez H September 10, 2022 EADV 2022 Atopic Dermatitis

Abrocitinib Reduces the Levels of Key Biomarkers Associated With Atopic Dermatitis in the Skin of Patients With Moderate-to-Severe Atopic Dermatitis

View Presentation
Oral Presentation
Pourang A, Kohli I, Ezekwe N, Parks-Miller A, Mohammad T, Huggins R, Lim H, Deal LS, Lukic T, Zhang F, Hamzavi I September 10, 2022 EADV 2022 Vitiligo

Assessing the Reliability of Vitiligo Area Scoring Index with Digital Images of Vitiligo

View Presentation
Poster
Holmes S, Rudnicka L, Blauvelt A, Zlotogorski A, Candiani JO, Edwards RA, Sadrarhami MM, Wolk R, Tran H September 10, 2022 EADV 2022 Alopecia

Association Between Early Eyebrow/Eyelash Assessments and Subsequent Scalp Hair Regrowth in Patients With Alopecia Areata Treated With Ritlecitinib: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

View Presentation
Oral Presentation
Bissonnette R, Worm M, Shi V, Zhang F, Chan G, Bratt T, Kerkmann U, Clibborn C September 10, 2022 EADV 2022 Atopic Dermatitis

Efficacy of Abrocitinib and Dupilumab on Chronic Hand Eczema in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Phase 3 JADE DARE Study

View Presentation
Poster
Zhang X, Magnolo N, Mizuashi M, Mesinkovska N, Shapiro J, Zhang F, Kerkmann U, Law E, Wolk R, Schaefer G September 10, 2022 EADV 2022 Alopecia

Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

View Presentation
Poster
Blume-Peytavi U, Harcha JWG, Yang Q, Schmieder GJ, Hordinsky MK, Micali G, Ohyama M, Takiya L, Zhang F, Schaefer G, Wolk R, Kerkmann U September 10, 2022 EADV 2022 Alopecia

Evaluation of Response to Ritlecitinib (PF-06651600) Treatment Based on SALT Improvement Scores in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

View Presentation
Poster
King B, Bergfeld W, Brzewski P, Aşkin Ö, Passeron T, Randhawa S, Law E, Edwards RA, Wolk R, Zwillich SH, Lejeune A September 10, 2022 EADV 2022 Alopecia

Impact of disease history on the efficacy of ritlecitinib (PF-06651600) in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

View Presentation
Poster
Anderson P, Marwaha S, Piercy J, Law EH, Wolk R, Schaefer G, Neary MP September 10, 2022 EADV 2022 Alopecia

Impact of Scalp Hair Loss on Treatment Patterns and Physician Satisfaction with Disease Control for Alopecia Areata Patients in Europe

View Presentation